Genetics & Gene testing
Genetic testing - identifies changes in genes that can cause health problems. It is mainly used to diagnose and individualize treatment for inherited and rare diseases, as well as for various types of cancer.
When should I have a genetic test?Your doctor may suggest that you should have a genetic/ genomic test if:
Why should I have genetic testing?
Your doctor may suggest you undergo genetic testing because:
If you have questions, talk to your physician about genetic testing or contact one of our scientific advisors scientific.support@genekor.com
Why is a genetic test so important?
A genetic test:
Is Genetic Counselling provided at Genekor?
At Genekor, we provide Free Genetic Counseling to all patients who wish to be tested.
Based on your personal and family health history, your doctor may referred you for genetic counselling. Find out more information here!
In which cases our scientific consultants will be useful:
It detects inherited cancer and helps in the management of the patient and/or family.
It detects inherited cardiovascular diseases and helps in the prevention and management of their effects.
It indicates the pharmaceutical substances that are metabolized properly by our body and those that we should avoid.
It indicates the pharmaceutical substances that are metabolized properly by our body and those that we should avoid. Helps determine the metabolic pathway of thiopurine drugs. It helps assess the risk of developing severe myelosuppression after administration.
Determines the metabolic pathway of the drug substance Siponimod, which is administered to patients with multiple sclerosis.
Determines the metabolic pathway of the drug substance Warfarin, which is administered to patients for the control of severe thrombolytic conditions.
It identifies the potential for clopidogrel variation in patients with cardiovascular diseases, and it determines the appropriate dosage for the best possible management of patients.
It identifies the potential for clopidogrel variation in patients with cardiovascular diseases, and it determines the appropriate dosage for the best possible management of patients.
The Oncotype DX® breast cancer gene test can help in deciding whether or not to start chemotherapy as part of treatment in early breast cancer.
It also determines the likelihood of a future recurrence of cancer.
Multi-gene test that analyzes the biology of the tumor in Non-Small Cell Lung Cancer, and helps individualize the treatment.
Multi-gene test designed to select the optimal targeted treatment for patients with colon cancer.
Multi-gene test for the detection and monitoring of gene mutations associated with targeted treatments for many types of cancer. For the test, only a blood sample is required.
Multigene Liquid Biopsy Test for postmenopausal women with recurrent or metastatic breast cancer ER+, HER2
Multigene test that analyzes tumor physiology and biomarkers of immunotherapy and PARP inhibition to design an effective personalized treatment plan.
Molecular Profiling of the tumor using liquid biopsy
A pioneering test for the early detection and early diagnosis of pancreatic cancer
The iGenome® gene test analyses the entire genome, increasing the chances of diagnosing inherited genetic diseases
The MyWES® test is based on WES – Whole Exome Sequencing analysis and performs a complete screening of over 20,000 genes for the detection and diagnosis of genetic diseases.
Xome Clinical Exome for the diagnosis of genetic diseases.
Molecular Detection of Minimal Residual Disease in Blood that Detects Earlier than Standard Techniques if Cancer is Still Present.
Detects inherited breast and ovarian cancer from a simple blood sample.
It identifies patients with inherited and non-inherited BRCA1 and BRCA2 gene mutations who could benefit from PARP inhibitor therapy.
The RediScore® test is recommended primarily in all patients with ovarian cancer, but also where PARP inhibitor therapy is under investigation for treatment or maintenance of the patient.
Determines the prognosis in patients with Stage II colon cancer (CC) and identifies
patients with an increased potential of developing Lynch syndrome; Predicts 5-FU treatment and response to immunotherapy.
In the case of biomarkers that require single-gene testing.
Detects prostate cancer with high accuracy.
Determines patients’ response to immunotherapy by determining the expression of PD-L1 protein.
FDA-approved, independent predictive biomarker for the response to immunotherapy in many types of cancer, including lung cancer.
A series of multi-gene tests, which analyze genes associated with inherited cardiovascular diseases for the diagnosis, prognosis and the determination of the appropriate treatment and adjustment.
Gene Testing for Thrombophilia
The iGenome® gene test analyses the entire genome, increasing the chances of diagnosing inherited genetic diseases
The MyWES® test is based on WES – Whole Exome Sequencing analysis and performs a complete screening of over 20,000 genes for the detection and diagnosis of genetic diseases.
Xome Clinical Exome for the diagnosis of genetic diseases.
A series of multi-gene tests, which analyze genes associated with inherited neurological disorders, helping to confirm clinical diagnosis, prognosis and determination of the appropriate disease management.
The iGenome® gene test analyses the entire genome, increasing the chances of diagnosing inherited genetic diseases
The MyWES® test is based on WES – Whole Exome Sequencing analysis and performs a complete screening of over 20,000 genes for the detection and diagnosis of genetic diseases.